LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Giardiello, Marco; Liptrott, Neill J.; McDonald, Tom O.; Moss, Darren; Siccardi, Marco; Martin, Phil; Smith, Darren; Gurjar, Rohan; Rannard, Steve P.; Owen, Andrew (2016)
Publisher: Nature Publishing Group
Journal: Nature Communications
Languages: English
Types: Article
Subjects: B800, RM, B200, Article
Considerable scope exists to vary the physical and chemical properties of nanoparticles, with subsequent impact on biological interactions; however, no accelerated process to access large nanoparticle material space is currently available, hampering the development of new nanomedicines. In particular, no clinically available nanotherapies exist for HIV populations and conventional paediatric HIV medicines are poorly available; one current paediatric formulation utilizes high ethanol concentrations to solubilize lopinavir, a poorly soluble antiretroviral. Here we apply accelerated nanomedicine discovery to generate a potential aqueous paediatric HIV nanotherapy, with clinical translation and regulatory approval for human evaluation. Our rapid small-scale screening approach yields large libraries of solid drug nanoparticles (160 individual components) targeting oral dose. Screening uses 1 mg of drug compound per library member and iterative pharmacological and chemical evaluation establishes potential candidates for progression through to clinical manufacture. The wide applicability of our strategy has implications for multiple therapy development programmes.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Caruso, F., Hyeon, T. & Rotello, V. M. Nanomedicine. Chem. Soc. Rev. 41, 2537-2538 (2012).
    • 2. McDonald, T. O. et al. in Global Approaches to Health and Safety Issues (ed. Dolez, P. I.) (Elsevier, 2015).
    • 3. Owen, A. & Rannard, S. Considerations for clinically-relevant nanomedicine therapies for chronic diseases. Nanomedicine 20, 3109-3119 (2015).
    • 4. Sosnik, A., Seremeta, K. P., Imperiale, J. C. & Chiappetta, D. A. Novel formulation and drug delivery strategies for the treatment of pediatric povertyrelated diseases. Expert Opin. Drug Deliv. 9, 303-323 (2012).
    • 5. World Health Organisation. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. ISBN 978 92 4 150956 5 (2015).
    • 6. Williams, III R. O., Watts, A. B. & Miller, D. A. Formulating Poorly Water Soluble Drugs (Springer Science & Business Media, 2011).
    • 7. Olagunju, A., Owen, A. & Cressey, T. R. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 13, 1501-1522 (2012).
    • 8. Zhang, H. D. et al. Formation and enhanced biocidal activity of water-dispersable organic nanoparticles. Nat. Nanotechnol. 3, 506-511 ð2008Þ:
    • 9. McDonald, T. O. et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization and in vitro-in vivo extrapolation. Adv. Healthc. Mater. 3, 400-411 (2014).
    • 10. U.S. Food and Drug Administration Center for Drug Evaluation and Research Inactive Ingredient Database. Available at http://www.accessdata.fda.gov/ scripts/cder/iig/index.cfm. (accessed on 25 January 2016).
    • 11. McDonald, T. O. et al. Multi-component organic nanoparticles for fluorescence studies in biological systems. Adv. Funct. Mater. 22, 2469-2478 (2012).
    • 12. Giardiello, M. et al. Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles. J. Mater. Chem. 22, 24744-24752 (2012).
    • 13. Freeling, J. P., Koehn, J., Shu, C., Sun, J. & Ho, R. J. Y. Anti-hiv drugcombination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res. Hum. Retroviruses 31, 107-114 (2015).
    • 14. Martin, P. et al. Augmented inhibition of CYP3A4 in human primary hepatocytes by ritonavir solid drug nanoparticles. Mol. Pharm. 12, 3556-3568 (2015).
    • 15. Reddy, B. P., Reddy, K. R., Reddy, R. R., Reddy, D. M. & Reddy, K. S. C. Polymorphs of lopinavir. US patent 8445506 filed 6 Feb. 2009, and published 21 May 2013.
    • 16. Schimpel, C. et al. Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles. Mol. Pharm. 11, 808-818 (2014).
    • 17. Burke, P. A. et al. Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. Pharm. Res. 21, 500-506 (2004).
    • 18. Authorised U.S. Pharmacopoeia Pending Monograph Version 1, Lopinavir (2009). Available from http://www.usp.org/sites/default/files/usp_pdf/EN/ USPNF/pendingStandards/m3545.pdf. (accessed on 25 January 2016).
    • 19. Williams, J. et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine 8, 1807-1813 (2013).
    • 20. Nelson, A. G. et al. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control. Release 219, 669-680 (2015).
    • 21. von Hentig, N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today 43, 221-247 (2007).
    • 22. Kaletra Full Prescribing information. Available from http://www.rxabbvie.com/ pdf/kaletratabpi.pdf. (accessed on 27 September 2016).
    • 23. Lorusso, D. et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 18, 1159-1164 (2007).
    • 24. Aula, S. et al. Biophysical, biopharmaceutical and toxicological significance of biomedical nanoparticles. RSC Adv. 5, 47830-47859 (2015).
    • 25. Bosgra, S., van Eijkeren, J., Bos, P., Zeilmaker, M. & Slob, W. An improved model to predict physiologically based model parameters and their interindividual variability from anthropometry. Crit. Rev. Toxicol. 42, 751-767 (2012).
    • 26. Yu, L. X. & Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186, 119-125 (1999).
    • 27. Poulin, P. & Theil, F.-P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
    • 28. Siccardi, M. et al. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol. 1, 4 (2013).
    • 29. Rajoli, R. K. et al. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin. Pharmacokinet. 54, 639-650 (2015).
    • 30. Kumar, G. N. et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21, 1622-1630 (2004).
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Funded by projects

Cite this article